ARRIVENT BIOPHARMA, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARRIVENT BIOPHARMA, INC. (AVBP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 4.33 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-05
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-06-30 was 2.67M shares, a 88.11% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 2.55M shares, a 88.64% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-06-30 was 22.44M shares.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 22.43M shares.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 4.33M shares, a 71.02% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.53M shares, a 88.09% decline from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 21.25M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | 4.33M shares 10-K · filed 2026-03-05 | |||
| 2024-12-31 | 2.53M shares 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 2.53M shares 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | 2.67M shares 10-Q · filed 2024-08-14 | 2.67M shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 2.55M shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 21.25M shares 10-K · filed 2025-03-03 | |||
| 2023-09-30 | 21.34M shares 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 22.44M shares 10-Q · filed 2024-08-14 | 22.44M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 22.43M shares 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |